Author

Govinda J. Weerakkody

Observed names: G Weerakkody, G. Weerakkody, G.J. Weerakkody, GOVINDA J. WEERAKKODY, Govinda J Weerakkody, Govinda Weerakkody, Govinda j. Weerakkody, Govinda. Weerakkody

Institution: Eli Lilly (United States)

Observed institutions: Brigham and Women's Hospital, Hartford Hospital, Cleveland Clinic, Harvard University, Eli Lilly (United States), Universidade de São Paulo, Trillium Health Centre, UNSW Sydney, Trinity Mother Frances Hospitals and Clinics, Thrombolysis in Myocardial Infarction Study Group, Université Pierre-et-Marie-Curie, The University of Adelaide, Columbia University, University of Edinburgh, Mississippi State University

ORCID: 0000-0003-0595-5554

Observed ORCID: 0000-0003-0595-5554

OpenAlex ID: A5079645471

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

2007 · Stephen D. Wiviott, Eugene Braunwald, et al. · New England Journal of Medicine · 6,813

PDF

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

2017 · A. Michael Lincoff, Stephen J. Nicholls, et al. · New England Journal of Medicine · 800

PDF

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

2021 · Stefano Del Prato, Steven E Kahn, et al. · The Lancet · 679

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

2005 · Stephen D. Wiviott, Elliott M. Antman, et al. · Circulation · 382

PDF

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

2022 · Naveed Sattar, Darren K. McGuire, et al. · Nature Medicine · 345

PDF

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

2006 · Stephen D. Wiviott, Elliott M. Antman, et al. · American Heart Journal · 324

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

2023 · Stephen J. Nicholls, Deepak L Bhatt, et al. · American Heart Journal · 246

Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort

2012 · Peter K. Smith, Lawrence T. Goodnough, et al. · Journal of the American College of Cardiology · 203

Limits of Retrospective Power Analysis

1998 · Patrick D. Gerard, David R. Smith, et al. · Journal of Wildlife Management · 163

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

2008 · S. A. Murphy, E. M. Antman, et al. · European Heart Journal · 142

PDF

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

2015 · Stephen J. Nicholls, A. Michael Lincoff, et al. · American Heart Journal · 93

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

2009 · Rebecca E. Wrishko, C. Steven Ernest, et al. · The Journal of Clinical Pharmacology · 84

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

2024 · Michael R. Zile, Barry A. Borlaug, et al. · Circulation · 73

Comparison of Speed of Onset of Platelet Inhibition After Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation With Responder Status

2007 · Govinda J. Weerakkody, Joseph A. Jakubowski, et al. · The American Journal of Cardiology · 67

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

2011 · Jeffrey S. Riesmeyer, Daniel E. Salazar, et al. · The Journal of Clinical Pharmacology · 55

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease

2018 · Steven E. Nissen, Sreekumar G. Pillai, et al. · JAMA Cardiology · 50

PDF

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

2023 · Julio Rosenstock, Luis Vázquez, et al. · Diabetes Care · 45

PDF

Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

2007 · Govinda J. Weerakkody, Joseph A. Jakubowski, et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 37

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

2020 · Venu Menon, Anirudh Kumar, et al. · BMJ Open Diabetes Research & Care · 27

PDF

Clopidogrel poor responders: An objective definition based on Bayesian classification

2007 · Govinda J. Weerakkody, John T. Brandt, et al. · Platelets · 26

Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis

2025 · Kieren J. Mather, Andrea Mari, et al. · Diabetes Obesity and Metabolism · 20

PDF

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis

2012 · Lawrence T. Goodnough, Peter K. Smith, et al. · Journal of Thoracic and Cardiovascular Surgery · 20

PDF

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy

2019 · Venu Menon, Anirudh Kumar, et al. · Journal of the American Heart Association · 19

Bounds for the Maximum Likelihood Estimates in Two-Parameter Gamma Distribution

2000 · Hai Dang, Govinda Weerakkody · Journal of Mathematical Analysis and Applications · 14

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

2022 · Darren K. McGuire, David D’Alessio, et al. · Cardiovascular Diabetology · 13

PDF

Works count: 59

Citation count: 10,880

H-index: 20

I10-index: 32